183 related articles for article (PubMed ID: 24185104)
1. 14-3-3σ attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.
Kim IK; Park SM; Cho HJ; Baek KE; Nam IK; Park SH; Ryu KJ; Ryu J; Choi J; Hong SC; Kim JW; Lee CW; Kang SS; Yoo J
Oncotarget; 2013 Nov; 4(11):2045-56. PubMed ID: 24185104
[TBL] [Abstract][Full Text] [Related]
2. VEGF-C mediates RhoGDI2-induced gastric cancer cell metastasis and cisplatin resistance.
Cho HJ; Kim IK; Park SM; Baek KE; Nam IK; Park SH; Ryu KJ; Choi J; Ryu J; Hong SC; Jeong SH; Lee YJ; Ko GH; Kim J; Won Lee C; Soo Kang S; Yoo J
Int J Cancer; 2014 Oct; 135(7):1553-63. PubMed ID: 24585459
[TBL] [Abstract][Full Text] [Related]
3. RhoGDI2 confers gastric cancer cells resistance against cisplatin-induced apoptosis by upregulation of Bcl-2 expression.
Cho HJ; Baek KE; Park SM; Kim IK; Nam IK; Choi YL; Park SH; Im MJ; Choi J; Ryu J; Kim JW; Lee CW; Kang SS; Yoo J
Cancer Lett; 2011 Dec; 311(1):48-56. PubMed ID: 21752536
[TBL] [Abstract][Full Text] [Related]
4. FBXL5 attenuates RhoGDI2-induced cisplatin resistance in gastric cancer cells.
Wu WD; Wang M; Ding HH; Qiu ZJ
Eur Rev Med Pharmacol Sci; 2016 Jun; 20(12):2551-7. PubMed ID: 27383304
[TBL] [Abstract][Full Text] [Related]
5. PLCγ is required for RhoGDI2-mediated cisplatin resistance in gastric cancer.
Cho HJ; Baek KE; Nam IK; Park SM; Kim IK; Park SH; Im MJ; Ryu KJ; Yoo JM; Hong SC; Kim JW; Lee CW; Yoo J
Biochem Biophys Res Commun; 2011 Oct; 414(3):575-80. PubMed ID: 21986528
[TBL] [Abstract][Full Text] [Related]
6. RhoGDI2 promotes epithelial-mesenchymal transition via induction of Snail in gastric cancer cells.
Cho HJ; Park SM; Kim IK; Nam IK; Baek KE; Im MJ; Yoo JM; Park SH; Ryu KJ; Han HT; Kim HJ; Hong SC; Kim KD; Pak Y; Kim JW; Lee CW; Yoo J
Oncotarget; 2014 Mar; 5(6):1554-64. PubMed ID: 24721928
[TBL] [Abstract][Full Text] [Related]
7. Proteomics-based strategy to delineate the molecular mechanisms of RhoGDI2-induced metastasis and drug resistance in gastric cancer.
Cho HJ; Baek KE; Kim IK; Park SM; Choi YL; Nam IK; Park SH; Im MJ; Yoo JM; Ryu KJ; Oh YT; Hong SC; Kwon OH; Kim JW; Lee CW; Yoo J
J Proteome Res; 2012 Apr; 11(4):2355-64. PubMed ID: 22364609
[TBL] [Abstract][Full Text] [Related]
8. RNA interference-mediated knockdown of RhoGDI2 induces the migration and invasion of human lung cancer A549 cells via activating the PI3K/Akt pathway.
Niu H; Wu B; Peng Y; Jiang H; Zhang Y; Wang J; Zhang Y; He P
Tumour Biol; 2015 Jan; 36(1):409-19. PubMed ID: 25266803
[TBL] [Abstract][Full Text] [Related]
9. RhoGDI2 is associated with HGF-mediated tumor invasion through VEGF in stomach cancer.
Koh SA; Kim MK; Lee KH; Kim SW; Kim JR
Clin Exp Metastasis; 2014 Oct; 31(7):805-15. PubMed ID: 25253431
[TBL] [Abstract][Full Text] [Related]
10. 14-3-3 Sigma Protein Contributes to Hepatocyte Growth Factor-mediated Cell Proliferation and Invasion
Jung JY; Koh SA; Lee KH; Kim JR
Anticancer Res; 2022 Jan; 42(1):519-530. PubMed ID: 34969762
[TBL] [Abstract][Full Text] [Related]
11. TRIM25 is associated with cisplatin resistance in non-small-cell lung carcinoma A549 cell line via downregulation of 14-3-3σ.
Qin X; Qiu F; Zou Z
Biochem Biophys Res Commun; 2017 Nov; 493(1):568-572. PubMed ID: 28867193
[TBL] [Abstract][Full Text] [Related]
12. RhoGDI2 expression is associated with tumor growth and malignant progression of gastric cancer.
Cho HJ; Baek KE; Park SM; Kim IK; Choi YL; Cho HJ; Nam IK; Hwang EM; Park JY; Han JY; Kang SS; Kim DC; Lee WS; Lee MN; Oh GT; Kim JW; Lee CW; Yoo J
Clin Cancer Res; 2009 Apr; 15(8):2612-9. PubMed ID: 19351766
[TBL] [Abstract][Full Text] [Related]
13. Tubeimoside I sensitizes cisplatin in cisplatin-resistant human ovarian cancer cells (A2780/DDP) through down-regulation of ERK and up-regulation of p38 signaling pathways.
Liu HZ; Yu C; Yang Z; He JL; Chen WJ; Yin J; Li WM; Liu HT; Wang YX
Mol Med Rep; 2011; 4(5):985-92. PubMed ID: 21687949
[TBL] [Abstract][Full Text] [Related]
14. Depletion of RhoGDI2 expression inhibits the ability of invasion and migration in pancreatic carcinoma.
Yi B; Hu Y; Qin G; Gu W; Zhu X; He S; Zhou J; Li D
Int J Mol Med; 2014 Jul; 34(1):205-12. PubMed ID: 24788627
[TBL] [Abstract][Full Text] [Related]
15. 14-3-3σ confers cisplatin resistance in esophageal squamous cell carcinoma cells via regulating DNA repair molecules.
Lai KK; Chan KT; Choi MY; Wang HK; Fung EY; Lam HY; Tan W; Tung LN; Tong DK; Sun RW; Lee NP; Law S
Tumour Biol; 2016 Feb; 37(2):2127-36. PubMed ID: 26346170
[TBL] [Abstract][Full Text] [Related]
16. 14-3-3σ downregulation suppresses ICC metastasis via impairing migration, invasion, and anoikis resistance of ICC cells.
Yang Z; Jin Q; Hu W; Dai L; Xue Z; Man D; Zhou L; Xie H; Wu J; Zheng S
Cancer Biomark; 2017 Jul; 19(3):313-325. PubMed ID: 28482619
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological inhibition of DUSP6 suppresses gastric cancer growth and metastasis and overcomes cisplatin resistance.
Wu QN; Liao YF; Lu YX; Wang Y; Lu JH; Zeng ZL; Huang QT; Sheng H; Yun JP; Xie D; Ju HQ; Xu RH
Cancer Lett; 2018 Jan; 412():243-255. PubMed ID: 29050982
[TBL] [Abstract][Full Text] [Related]
18. Knockdown of RhoGDI2 represses human gastric cancer cell proliferation, invasion and drug resistance via the Rac1/Pak1/LIMK1 pathway.
Zeng Y; Ren M; Li Y; Liu Y; Chen C; Su J; Su B; Xia H; Liu F; Jiang H; Ling H; Zeng X; Su Q
Cancer Lett; 2020 Nov; 492():136-146. PubMed ID: 32860848
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin induces chemoresistance through the PTGS2-mediated anti-apoptosis in gastric cancer.
Lin XM; Li S; Zhou C; Li RZ; Wang H; Luo W; Huang YS; Chen LK; Cai JL; Wang TX; Zhang QH; Cao H; Wu XP
Int J Biochem Cell Biol; 2019 Nov; 116():105610. PubMed ID: 31518663
[TBL] [Abstract][Full Text] [Related]
20. DeltaNp63alpha-mediated induction of epidermal growth factor receptor promotes pancreatic cancer cell growth and chemoresistance.
Danilov AV; Neupane D; Nagaraja AS; Feofanova EV; Humphries LA; DiRenzo J; Korc M
PLoS One; 2011; 6(10):e26815. PubMed ID: 22053213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
